This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in…
molecule
2 years ago ●
1 min read
The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of…
molecule
2 years ago ●
1 min read
The Galapagos CFTR potentiator, GLPG2451, is an oral, once-daily clinical candidate for cystic fibrosis (5-80 mg QD). It was advanced…
molecule
2 years ago ●
1 min read
The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for…
molecule
2 years ago ●
1 min read
The Merck LRRK2 inhibitor, MLi-2, is an orally available tool compound that is structurally distinct from the LRRK2 inhibitor GNE-7915.…
molecule
2 years ago ●
1 min read
The GSK αvβ6 integrin inhibitor, “compound 1,” or GSK 3008348 is a previously reported IPF clinical candidate that is a…
molecule
2 years ago ●
1 min read
Load More
